Literature DB >> 29019471

Infantile hemangioma: factors causing recurrence after propranolol treatment.

Lei Chang1, Dongze Lv1, Zhang Yu1, Gang Ma1, Hanru Ying1, Yajing Qiu1, Yifei Gu1, Yunbo Jin1, Hui Chen1, Xiaoxi Lin1.   

Abstract

BackgroundPropranolol is the first-choice treatment for severe infantile hemangioma (IH). However, 10- 30% of lesions relapse after propranolol treatment. The mechanisms underlying IH recurrence after propranolol treatment have not been completely elucidated.MethodsThis study combined an examination of hemodynamic changes with research regarding hemangioma stem cells (hscs) with differentially expressed microRNAs (miRNAs) to identify the factors affecting IH recurrence after propranolol treatment. Hemodynamic changes were monitored in 21 recurrent cases using high-frequency color Doppler ultrasound, and hscs were treated with different concentrations of propranolol. The levels of differentially expressed miRNAs and the activity of related pathways were then compared between 18 recurrent and 20 non-recurrent IH cases.ResultsDuring treatment, lesion depth and vessel density decreased, and the lesion resistance index increased. Obvious lesions and vessel signals were observed in recurrent cases compared with non-recurrent cases. Propranolol effectively inhibited hscs proliferation. Twenty-two differentially expressed miRNAs were found in the recurrent group compared with the non-recurrent group.ConclusionRecurrence may be attributed to a combination of events. Serum biomarkers and drug treatments for IH recurrence must be studied further.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29019471     DOI: 10.1038/pr.2017.220

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  38 in total

1.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

2.  Oral Propranolol for Infantile Hemangioma.

Authors:  Arturo Tozzi
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

3.  Late rebound of infantile hemangioma after cessation of oral propranolol.

Authors:  Nancy Shehata; Julie Powell; Josée Dubois; Afshin Hatami; Elizabeth Rousseau; Sandra Ondrejchak; Catherine McCuaig
Journal:  Pediatr Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.588

4.  Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China.

Authors:  Lei Chang; Xiaoxiao Ye; Yajing Qiu; Gang Ma; Yunbo Jin; Hui Chen; Dongze Lv; Wenxin Yu; Xi Yang; Tianyou Wang; Xiaoxi Lin
Journal:  Ann Plast Surg       Date:  2016-05       Impact factor: 1.539

5.  Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment.

Authors:  Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Sarah L Chamlin; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Anthony J Mancini; Denise W Metry; Brandon Newell; Amy J Nopper; Ilona J Frieden
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

6.  A randomized, controlled trial of oral propranolol in infantile hemangioma.

Authors:  Christine Léauté-Labrèze; Peter Hoeger; Juliette Mazereeuw-Hautier; Laurent Guibaud; Eulalia Baselga; Gintas Posiunas; Roderic J Phillips; Hector Caceres; Juan Carlos Lopez Gutierrez; Rosalia Ballona; Sheila Fallon Friedlander; Julie Powell; Danuta Perek; Brandie Metz; Sebastien Barbarot; Annabel Maruani; Zsuzsanna Zsofia Szalai; Alfons Krol; Olivia Boccara; Regina Foelster-Holst; Maria Isabel Febrer Bosch; John Su; Hana Buckova; Antonio Torrelo; Frederic Cambazard; Rainer Grantzow; Orli Wargon; Dariusz Wyrzykowski; Jochen Roessler; Jose Bernabeu-Wittel; Adriana M Valencia; Przemyslaw Przewratil; Sharon Glick; Elena Pope; Nicholas Birchall; Latanya Benjamin; Anthony J Mancini; Pierre Vabres; Pierre Souteyrand; Ilona J Frieden; Charles I Berul; Cyrus R Mehta; Sorilla Prey; Franck Boralevi; Caroline C Morgan; Stephane Heritier; Alain Delarue; Jean-Jacques Voisard
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

7.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Authors:  Xi Chen; Yi Ba; Lijia Ma; Xing Cai; Yuan Yin; Kehui Wang; Jigang Guo; Yujing Zhang; Jiangning Chen; Xing Guo; Qibin Li; Xiaoying Li; Wenjing Wang; Yan Zhang; Jin Wang; Xueyuan Jiang; Yang Xiang; Chen Xu; Pingping Zheng; Juanbin Zhang; Ruiqiang Li; Hongjie Zhang; Xiaobin Shang; Ting Gong; Guang Ning; Jun Wang; Ke Zen; Junfeng Zhang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

8.  Diagnosis and Management of Infantile Hemangioma.

Authors:  David H Darrow; Arin K Greene; Anthony J Mancini; Amy J Nopper
Journal:  Pediatrics       Date:  2015-10       Impact factor: 7.124

Review 9.  MicroRNAs: opening a new vein in angiogenesis research.

Authors:  Jason E Fish; Deepak Srivastava
Journal:  Sci Signal       Date:  2009-01-06       Impact factor: 8.192

10.  IGF2-derived miR-483 mediated oncofunction by suppressing DLC-1 and associated with colorectal cancer.

Authors:  Hengmi Cui; Yuan Liu; Jingrui Jiang; Yangyang Liu; Zhe Yang; Shaogen Wu; Wangsen Cao; Isabelle H Cui; Chenggong Yu
Journal:  Oncotarget       Date:  2016-07-26
View more
  3 in total

1.  Long non-coding RNA breast cancer-associated transcript 54 sponges microRNA-1269b to suppress the proliferation of hemangioma-derived endothelial cells.

Authors:  Zhonjun Lv; Ke Yang; Ya Wang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

2.  Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration.

Authors:  Horacio Gomez-Acevedo; Yuemeng Dai; Graham Strub; Carrie Shawber; June K Wu; Gresham T Richter
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

3.  Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis.

Authors:  Ting Zhang; Yingying Qian; Chunyu Yuan; Yafen Wu; Hua Qian; Hui Lu; Cui Hu; Wei Li
Journal:  Biomed Res Int       Date:  2021-10-16       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.